BTK and acute myeloid leukemia: The anti-proliferative effects of BTK inhibition in human AML are mediated via inhibition of downstream AKT, MAPK, ERK and Nuclear Factor-KappaB (NF-κB) pro-survival signalling however the upstream drivers of BTK activation in human AML have yet to be fully characterised.